PAR 1.96% 25.0¢ paradigm biopharmaceuticals limited..

Video: Paradigm Biopharmaceuticals (ASX:PAR) conducting Phase 3 osteoarthritis trial, page-18

  1. 1,705 Posts.
    lightbulb Created with Sketch. 1856
    If he was in a board role, maybe. But as a consultant? How challenging can you be?

    Also, costs are what threatens to send the company into a tailspin. SW is there to focus (part-time) on assisting with partnerships. In footy terms, that's like hiring a goal-kicking coach when you're shipping 30 goals a game.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.